Meta-analysis finds lower bleeding risk with apixaban and rivaroxaban vs VKAs in dialysis patients with AF

Photo by Trust "Tru" Katsande / Unsplash

Renal failure Published May 14, 2026 Medically reviewed May 14, 2026 Study authors: Wu Xiaoyuan, Meng Jie, Yang Yu, Sheng Dacheng, Liu Xin, Zhou Yilun PubMed ↗ DOI ↗ By Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

Key Takeaway

Consider apixaban or rivaroxaban as alternatives to VKAs in dialysis patients with AF, but recognize the evidence is inconclusive due to heterogeneity and limited RCT data.

This systematic review and meta-analysis evaluated the safety and efficacy of apixaban or rivaroxaban versus vitamin K antagonists (VKAs) in patients with atrial fibrillation undergoing dialysis. The analysis included both observational studies and randomized controlled trials, though the sample size and number of RCTs were limited.

Pooled results showed that apixaban and rivaroxaban were associated with a lower risk of major bleeding (RR 0.57; 95% CI 0.51-0.63), gastrointestinal bleeding (RR 0.66; 95% CI 0.57-0.76), and intracranial hemorrhage (RR 0.54; 95% CI 0.36-0.83) compared with VKAs. For efficacy outcomes, the direct oral anticoagulants were associated with reduced risks of stroke/systemic embolism (RR 0.57; 95% CI 0.46-0.72) and all-cause mortality (RR 0.73; 95% CI 0.63-0.83).

The authors noted substantial heterogeneity across studies. Importantly, the RCT-only analysis did not reach statistical significance due to limited sample size, and evidence regarding efficacy in preventing stroke/systemic embolism and all-cause mortality remains inconclusive. Optimal apixaban dosing is not established.

Clinicians should interpret these findings cautiously. While the meta-analysis suggests potential benefits of apixaban and rivaroxaban over VKAs in this population, the limitations of the evidence base—including reliance on observational data and heterogeneity—mean that large dedicated RCTs are needed to confirm these results and guide dosing.

Study Details

Study typeMeta analysis

EvidenceLevel 1

PublishedDec 2026

PMID42128628

View Original Abstract ↓

This study aimed to evaluate the comparative efficacy and safety of apixaban and rivaroxaban versus vitamin K antagonists (VKAs) in anticoagulation management in a dialysis population. PubMed, Embase, and the Cochrane Library were searched for studies comparing apixaban or rivaroxaban with VKAs in patients with atrial fibrillation (AF) undergoing dialysis. The primary efficacy endpoints included stroke/systemic embolism (SSE) and all-cause mortality. Safety outcomes encompassed major bleeding, intracranial hemorrhage, and gastrointestinal bleeding. Risk ratios (RR) with 95% confidence intervals (CI) were synthesized using random-effects models. The meta-analysis included three randomized controlled trials (RCTs) and eight observational studies. Pooled analyses showed that apixaban and rivaroxaban were associated with lower risks of major bleeding (RR 0.57, 95% CI: 0.51-0.63), gastrointestinal bleeding (RR 0.66, 95% CI: 0.57-0.76), and intracranial hemorrhage (RR 0.54, 95% CI: 0.36-0.83) compared with VKAs. Additionally, apixaban and rivaroxaban were associated with reduced risk of SSE (RR 0.57, 95% CI: 0.46-0.72) and all-cause mortality (RR 0.73, 95% CI:0.63-0.83), although substantial heterogeneity was present. Exploratory dose-stratified analyses suggested both standard- and low-dose apixaban regimens were associated with favorable efficacy and hemostatic safety relative to warfarin. Consistent numerical trends were observed in the RCT-only analysis, though none reached statistical significance owing to limited sample size. In conclusion, apixaban and rivaroxaban are associated with lower risks of bleeding compared with VKAs in patients with AF and ESRD. However, evidence regarding their efficacy in preventing SSE, all-cause mortality and the optimal apixaban dosing regimen remains inconclusive and requires validation in large, dedicated RCTs.